Research programme: inflammation and cancer therapeutics - Ampio Pharmaceuticals

Drug Profile

Research programme: inflammation and cancer therapeutics - Ampio Pharmaceuticals

Alternative Names: NCE-001

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Ampio Pharmaceuticals
  • Developer Ampio Pharmaceuticals; Syngene
  • Class Piperazines; Piperidines
  • Mechanism of Action Phosphoric monoester hydrolase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer; Glioblastoma; Inflammation; Inflammatory breast cancer; Renal cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Glioblastoma in India
  • 16 Jul 2016 No recent reports of development identified for research development in Inflammation in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top